Leading Edge Urology: 49th Duke Urologic Assembly and Duke Urologic Cancer Symposium

March 9, 2017 to March 12, 2017

The tremendous growth in the screening, detection, risk-stratification and management of urologic diseases and cancers is constantly changing the specialty of urology.  As a result imporements in the imaging and treatment of these conditions generate a great need for knowledge and up-to-date information for providers and health care professionals.  Emphasis will be placed on diagnostic evaluation, thereapeutic options, management of complication, and the use of new technologies that provide leading edge care to patients.

 

Learning Objectives

At the end of this activity, participants should be able to:

  • Review common coding questions, update CPT coding skills, ICD-10 coding, and modifiers in billing to optimize reimbursement
  • Recognize the role of robotic technology in surgical treatment of bladder cancer
  • Identify the role of ischemia on renal structure and function while performing partial nephrectomy
  • Propose a treatment strategy for the patient with Peyronie’s disease and erectile dysfunction by means of a critical review of surgical treatment with penile implants in the context of the AUA guidelines
  • Discuss the symptoms, diagnosis, evaluation and treatment of posterior urethral stenosis following the treatment of prostate cancer
  • State the current controversy around prostate cancer screening and begin to explore alternative strategies
  • Identify the current guidelines in hematuria work-up and to learn about advances in the detection of bladder cancer in these patients
  • Apply concepts that relate to imaging of prostate cancer using multipara metric MRI, specifically the utility of individual sequences for assessing tumors in different prostatic zones and in different clinical scenarios
  • Recognize the role of cross-sectional imaging in the evaluation of the patient with renal malignancies, including findings on CT that help to define the correct diagnosis as well as to understand the rationale for different imaging protocols for the patient suspected to have renal  malignancy, specifically in reference to reducing radiation dose and optimizing image quality
  • Discuss the newly FDA-approved immune checkpoint inhibitors in urothelial cancer and their integration into treatments for patients with metastatic urothelial carcinoma 
  • Discuss changes in the treatment landscape for metastatic renal cell carcinoma and integration of checkpoint inhibitors and cabozantinib for patients with advanced RCC
  • Analyze selected new pathologic entities and histologic features of metastatic prostate cancer
  • Recognize that post prostatectomy treatment incontinence is common and has significant impact on quality of life
  • Counsel patients regarding treatment options for post prostatectomy incontinence and the indications for those options including behavioral, medical and surgical
  • Describe and compare the various complications that can arise immediately and in the long term from radiation to the lower genitourinary tract including fistula, stricture, voiding dysfunction and incontinence
  • Treat and longitudinally follow patients who have complications from radiation therapy including surgical, medical and long-term follow-up
  • Incorporate surgical options for patients with lower genitourinary and upper genitourinary tract complications from radiation therapy into practice
  • Achieving a working knowledge of current technologies for imaged guided prostate cancer therapy
  • Learning methods to measure tissue response to various therapeutic approaches
  • Developing patient selection criteria for optimal results of image guided therapies
  • Describe some novel applications of hyperthermia in bladder cancer
  • Becoming familiar with the various pathologic variants of renal cell carcinoma and differentiating the molecular and genetic characteristics of these tumors
  • Learning optimal surgical and medical therapies of renal tumor types guided by biochemical and biological characteristics
  • Describe appropriate application of radiation oncology technology based on clinical evidence
  • Recognize how fever-range hyperthermia can influence cancer biology
  • Assess fundamental concepts of heat-targeted drug delivery for bladder cancer
  • Describe the lymphatic drainage of the prostate and the role of lymphadenectomy
  • Identify prostate cancer metastases and what oligometastatic prostate cancer is
  • Describe options for treating oligometastatic prostate cancer
Course summary
Available credit: 
  • 20.25 ANCC
  • 20.25 JA Credit - AH
Registration Opens: 
01/01/2017
Registration Expires: 
03/11/2018
Activity Starts: 
03/09/2017 - 12:00pm EST
Activity Ends: 
03/12/2017 - 10:00am EDT
JW Marriott Grande Lakes
Orlando, FL
United States

Available Credit

  • 20.25 ANCC
  • 20.25 JA Credit - AH
Please login or register to take this course.